Despite efficacy with pharmacological inhibition of SRC-3, complete amelioration of SRC-3 via knockout in vivo shows the specific induction of extreme lymphoproliferation of both T and B cells, eventually progressing into B-cell lymphoma with age. This evidence concerns the gene NCOA3 and B-cell non-Hodgkin lymphoma.